Serelaxin inhibits differentiation and fibrotic behaviors of cardiac fibroblasts by suppressing ALK‐5/Smad2/3 signaling pathway
Sign Up to like & getrecommendations! Published in 2018 at "Experimental Cell Research"
DOI: 10.1016/j.yexcr.2017.10.004
Abstract: Abstract Serelaxin, a recombinant form of human relaxin‐2, is currently regarded as a novel drug for treatment of acute heart failure. However, whether therapeutic effects of serelaxin are achieved by inhibiting cardiac fibrosis remains unclear.… read more here.
Keywords: cardiac fibroblasts; alk smad2; differentiation; serelaxin ... See more keywords